NASDAQ · Medical - Devices
APYX (APYX) Stock
$4.07
-1.21%
NASDAQ: APYX
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
HC Wainwright Initiates Apyx Medical at Buy With $7 Price Target
MT Newswires · Jul 13, 2026
Apyx Medical Corporation (APYX): a High Growth Micro-Cap Stock Improving Cellulite and Skin laxity
Insider Monkey · Jun 19, 2026
How The Apyx Medical (APYX) Story Is Shifting With AYON, GLP 1 Demand And 2026 Goals
Simply Wall St. · Jun 1, 2026
Body by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway
PR Newswire · May 27, 2026
What to Know About This Fund's $13.9 Million Exit From a Skyrocketing AI Power Play
Motley Fool · May 21, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held13.61%
Institutions Held49.60%
Institutions Float Held57.42%
Peer Comparison
About APYX
APYX is led by CEO Charles D. Goodwin, employs 220 people, headquartered in US, publicly traded since 2019.
APYX stock trades at $4.07 with a market capitalization of $171.39M. The stock is valued at a price-to-earnings (P/E) ratio of -17.90, price-to-book of 15.36, price-to-sales of 3.50. Over the past 52 weeks the stock has ranged between $1.59 and $5.08, and currently trades 19.9% below its 52-week high.
On profitability, APYX generates a return on equity (ROE) of -76.49%, return on capital employed of -40.00%, an operating margin of -7.70%, a net profit margin of -16.40%.